Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET. Company Participants. Nichol Ochsner - VP, IR and Corporate Communications Neil ...

Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...

Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms ...

Swiss pharmaceutical company Novartis has renewed its 15,865-square-foot office at Property & Building Corporation’s 10 ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

The "mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CA ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

"We are coming off a tremendously successful year. Our 2024 total revenue nearly achieved blockbuster status, and we are just ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Novartis spokesperson told News18 that the company is in the process of reviewing the minutes of the meeting and post ...